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ABSTRACT

ANALYSIS OF TUMOR SPECIFIC PROTEIN EXPRESSION IN GLIOBLASTOMA
MULTIFORME (GBMs) TUMORS-THROUGH IMMUNOHISTOCHEMISTRY
By

Amanda M. Wigand
GBM tumors are the most aggressive and, unfortunately, the most fatal form of brain
cancer. GBM tumors with isocitrate dehydrogenase-1 (IDH1) mutation being expressed,
lead to higher survival rates in patients that also have full resection of the tumor and
chemotherapy. Without this mutation, it is thought that tumors have a higher expression
of the protein Basigin and O6-methylguanine-DNA-methyltransferase (MGMT) present,
causing it to be more aggressive and less responsive to standard care. The objective of
this study was to understand the correlation between IDH1 mutation presence and the
expression of Basigin and MGMT. The expression of these proteins was observed in
tissues sections from GBM tumors. Proteins were labeled with a fluorescent antibody
and imaged with a confocal microscope. The tissue images were then analyzed using
Imaris software. It was shown that there was a significant difference between the
presence of the IDH1 mutation and Basgin, and also MGMT among all of the tissue
blocks.

i

Copyright by
Amanda M. Wigand
May 2016

ii

ACKNOWLEDGEMENTS
The amount of support that I have received since first coming to Northern Michigan
University my freshman year until now has been tremendous. I would like to especially
thank my undergraduate and graduate advisor, Dr. Robert Belton, for his help with my
research and always pushing me to find a solution. This research would not have been
possible without my research mentors Dr. John Lawrence, Cathy Bammert, Dr. Erich
Ottem, Dr. Robert Winn, Dr. Alan Rebertus, Dr. John Weiss, and Dr. VanGrisven. I
would also like to thank the Upper Michigan Brain Tumor Center’s intelligent graduate
and undergraduate students including Samantha Wightman, Marissa Kane, Chris
McMahon, Melanie Flaherty, and Bridget Waas. Most of all I would like to thank my
parents and Kevin Burek for their continued support during my time at Northern and
throughout life.

iii

TABLE OF CONTENTS
List of Figures .................................................................................................................................v
List of Symbols and Abbreviations ............................................................................................... vi
Introduction

..................................................................................................................................1

Chapter One: Literature review ......................................................................................................3
Cancer development and GBMs ..............................................................................3
Primary vs. secondary GBM ....................................................................................5
Morphology of GBM tumors ...................................................................................7
IDH1 ........................................................................................................................8
MGMT and Temozolomide .....................................................................................9
Basigin ...................................................................................................................11
Chapter Two: Experimental design ...............................................................................................14
Human GBM samples ............................................................................................14
Human GBM cell lines ..........................................................................................15
Immunoblotting and antibodies .............................................................................15
Histochemistry .......................................................................................................16
Immunostaining and confocal imaging ..................................................................17
Statistical analysis ..................................................................................................17
Chapter Three: Results ...................................................................................................................19
Hematoxylin and Eosin Analysis ...........................................................................19
Protein expression within GBM cell lines .............................................................19
Protein expression within GBM tissue blocks .......................................................20
Analysis of protein expression in GBM samples ...................................................21
Chapter Four: Discussion ..............................................................................................................22
References Cited ............................................................................................................................67

iv

LIST OF FIGURES

Figure 1: Isocitrate Dehydrogenase (IDH) enzyme function within human cells .........................26
Figure 2: Common Temozolomide-induced DNA lesions appear on guanine and adenine ..........27
Figure 3: Temozolomide is converted to MTIC within the body and contributes methyl or
alkyl chemical groups to the purines on DNA ...............................................................................28
Figure 4: Microvesicles and exosomes are membrane vesicles released from cells to the
extracellular space ..........................................................................................................................29
Figure 5a-e: H&E staining from GBM tumor blocks ....................................................................30
Figure 6: Immunoblotting of human cell lines with the MGMT antibody ....................................36
Figure 7: Immunoblotting of human cell lines with the Basigin antibody ....................................37
Figure 8: Immunoblotting of human cell lines with the IDH1 antibody .......................................38
Figure 9: Immunoblotting of human cell lines with the IDH1 mutant antibody ...........................39
Figure 10: Immunoblotting of human cell lines with the GAPDH antibody .................................40
Figure 11a-e: Immunofluorescence of block 5653 ........................................................................41
Figure 12a-e: Immunofluorescence of block 3331 ........................................................................45
Figure 13a-e: Immunofluorescence of block 4946 ........................................................................50
Figure 14a-e: Immunofluorescence of block 10168 ......................................................................55
Figure 15a-e: Immunofluorescence of block 8072 ........................................................................60
Figure 16a-b: Comparison of immunofluorescence and protein area ............................................65

v

LIST OF SYMBOLS AND ABBREVIATIONS

GBM- Glioblastoma Multiforme
IDH- Isocitrate Dehydrogenase
MGMT- O-6-methylguanine-DNA methyltranserfase
DNA- Deoxyribonucleic acid
CNS- Central nervous system
CSC- cancer stem cell
EGFR- Epidermal growth factor receptor
MDM2- Murine Double-Minute 2
VEGF- vascular endothelial growth factor
MVP- microvascular proliferations
AML- acute myelogenous leukemia
ALL- acute lympoblastic leukemia
CIMP- CpG island methylator phenotype
TMZ- Temozolomide
MMP-matrix metalloproteinase

vi

INTRODUCTION

Glioblastoma multiforme (GBM) tumors are the most common and aggressive
form of brain tumor in humans1. Death from GBM tumors is associated with the rapid
rate of tumor growth, which can double in size every two weeks. GBM tumors are
classified as either primary or secondary tumors. Primary GBMs generally form in older
individuals, and the tumors progress rapidly resulting in the quick onset of symptoms
and relatively short patient survival times2. These primary tumor types are the most
common and deadly form of GBMs. Secondary GBMs generally occur in people at age
forty-five or younger and represent ten percent of all GBMs3. Secondary GBMs tend to
grow at a slower rate and are more responsive to treatment, however they are, none-theless, deadly if not treated. GBM tumors appear heterogeneous in their composition, as
they will contain several different substances, including cystic minerals, calcium
deposits, blood vessels, and dead cells. Because of their location within the brain, GBMs
rarely metastasize to other regions of the body. However, presence of tumor tissue
within the brain results in significant morbidity as the tumor invades and crowds out
normal brain tissue 2.
The ability to distinguish between GBM tumors of differing severity is central
to the efforts to develop novel therapies. For example, many GBM tumors overexpress DNA repair enzymes like O-6-methylguanine-DNA methyltransferase
(MGMT), which makes them resistant to chemotherapy and radiotherapy treatments 4.
MGMT does not play a role in tumor development, it is mainly utilized for tumor
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maintenance. Identifying proteins associated with resistant GBM tumors is a necessary
first step in the process of developing novel therapies. Currently, our work is focused
upon three specific proteins known individually to play a significant role in the
development of GBM tumors: Basigin, MGMT, and IDH1.
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CHAPTER ONE: LITERATURE REVIEW

Cancer Development and GBMs
The development of cancer in humans can occur in response to many different
kinds of damage to DNA, including exposure to toxic substances, viruses, or radiation.
In all cases, the main hallmark of cancer development is the abnormal proliferation of
cells collectively, referred to as neoplasia. Tumors develop from normal cells in stages
as the cancer develops an ever-increasing ability to proliferate. Thus, the terms
hyperplasia, metaplasia, and dysplasia have been used to describe the increasing
proliferative capacity, with dysplastic tumors being the most aggressive cancers5.
Hyperplasia refers to tissues that appear normal but are growing inappropriately.
Metaplasia refers to tissues that are still exhibiting functional characteristics, but
demonstrate the overgrowth of one tissue or cell type over another. Lastly, cells or
tissues that appear abnormal and are clearly growing in an uncontrolled fashion are
referred to as dysplastic5. The multiple-hit hypothesis for tumor formation (also called
the Knudson hypothesis) states that dysplastic tumors contain cells with two or more
mutations to important growth regulatory genes6. For example, a mutation that
inactivates a gene that normally suppresses cell growth (tumor suppressor genes) can
result in a cell growing and dividing uncontrollably6. Such tumor suppressor genes act
as brakes to prevent abnormal cell growth. Conversely, mutations that activate normally
inactive genes or amplify genes that are not regularly transcribed, resulting in cell
proliferation, are referred to as proto-oncogenes. In this case, mutations to protooncogenes can convert them to oncogenes resulting in the production of proteins that
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are constitutively active and promote cell proliferation. The Knudson hypothesis
proposes that cells generally require both the inactivation of tumor suppressor genes
and the activation of proto-oncogenes to form dysplastic tumors5.
Within GBM tumors exists a population of cells that play a central role in tumor
progression. These so-called cancer stem cells (CSCs) are slow growing and possess
properties of stem cells, including the ability for self-renewal. Like other stem cells,
CSC appear to be resistant to chemotherapeutics, possess an enhanced ability to repair
damage to DNA, and are able to regenerate tumors following surgical removal of the
original tumor 7. Furthermore, CSC are able to divide without differentiating and thus
can provide a reservoir for the formation of new tumors 8. It is unknown whether the
CSCs are the cancer initiating cells of a GBM tumor, or whether they represent a
population of dysplastic cells that have de-differentiated to form stem cell-like cells.
It is widely accepted that brain tumors can arise from a number of different glial
cell types such as, glial progenitor cells, astrocytes, or oligodendrocytes, giving rise to
tumors of varying severity9. GBMs that arise from glia or other precursor cells within
the central nervous system (CNS) cause their specific pathologies as the tumors
proliferate in an uncontrolled fashion. A number of changes have been identified in
GBM tumors, including either an insensitivity or oversensitivity to cell autonomous
signals, or self-signaling, hypermethylation or hypomethylation of chromatin regions
surrounding key cellular growth or apoptosis genes, and specific mutations within the
DNA10. A particularly significant mutation found within GBMs and lower grade gliomas
occurs to the Isocitrate dehydrogenase 1 gene (IDH1). Point mutations to the IDH1 gene
can produce an arginine-to-histidine amino acid change at amino acid 132 of the IDH1
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enzyme (called the IDH1 R132H mutant).This mutation leads to sensitivity to reactive
oxidative species. Reactive oxidative species are a collection of molecules produced by
normal cellular metabolism that can cause cellular damage. In its normal state, it has
been shown that IDH1 may function to help maintain the redox state within the cell and
promote cellular defense against oxidative damage11. The point mutation to IDH
resulting in IDH1 R132H produces an oncogene that has a role in oncogenesis and may
be an important possibility for therapeutic interventions10.
GBM tumors tend to experience changes in the expression profiles for many
genes which confers a phenotype that resists treatment and promotes cancer growth; the
enzyme O-6-methylguanine-DNA methyltransferase (MGMT) falls in this category.
MGMT is a DNA repair enzyme that removes chemical adducts from damaged DNA,
preventing future damage, specifically from the O6 guanine residue12. The
chemotherapeutic drug Temozolomide (TMZ), which is the standard chemotherapy
agent used to treat GBM tumors, functions by adding alkyl or methyl groups to the N7
position of guanine, N3 position of adenine, and the O6 guanine residues4. TMZ induces
DNA damage, most importantly to the O6 guanine residue, the most cytotoxic location,
stimulating apoptotic processes that result in the death of the rapidly growing cells
found within the tumor. However, when a tumor cell overexpresses the MGMT enzyme,
such cancers can evolve resistance to alkylating therapeutic agents like TMZ13.
Therefore, a comprehensive understanding of the expression patterns for DNA repair
enzymes, such as MGMT, in patient tumors, is central in our efforts to effectively treat
GBM patients 4.
Primary vs. Secondary GBM
Primary and secondary tumors are thought to arise from different populations
5

and are characterized by different genetic changes within each 9. More importantly,
primary tumors tend to be more aggressive and arise in older populations, while
secondary tumors are less aggressive and occur in younger populations14. Primary
tumors often have genetic alterations including the loss of the proximal arm of
chromosome 10 (called LOH 10p), amplification of epidermal growth factor receptor
gene (EGFR) and Murine Double Minute-2 oncoprotein (MDM2) gene, and inactivating
mutations to the PTEN tumor suppressor gene14. Primary tumors also develop rapidly
after a short clinical history and with very little evidence of less malignant preceding
tumors15. Consequently, these tumors are extremely aggressive in their growth and
resistance to treatment, and result in a poor prognosis for patients14.
Secondary GBMs area characterized by a loss of the distal arm of chromosomes
19 and 22 (19q, 22q), and mutations in the TP53 tumor suppressor gene. Secondary
GBMs are more likely to develop from slow growing and well-differentiated low-grade
astrocytomas. These tumors have a tendency to slowly invade other brain tissues,
develop into an anaplastic astrocytomas, and eventually form secondary GBMs15. The
TP53 mutation is considered an early mutation in the sequence of tumor formation, as it
occurs in low-grade, diffuse astrocytomas as well as in most secondary GBMs14. TP53 is
commonly mutated in a number of different human cancer types as the p53 protein,
which is produced as a product of the TP53 gene, is a master regulator of the cell cycle
and is important for the suppression of tumor development. Inactivating mutations to
TP53 generally involve a single base substitution, and subsequent loss of the remaining
wild type allele16. TP53 mutations are known to be very diverse in their sequence
context, position and structure, and generally result in a missense mutation causing a
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single amino-acid change in the p53 protein16. Interestingly, TP53 mutations and IDH1
mutations are generally both present within secondary GBMs 3.
Morphological Characteristics of GBM tumors
GBM tumor tissue is heterogeneous in nature and can vary widely in both the
cellular and vascular forms. Analysis of tumor architecture is performed by
histochemical analysis of biopsied tissues. Histological analysis of tumors is the gold
standard utilized by pathologists to assess the ‘tumor grade’ of a patient. According the
World Health Organization (WHO), a grade IV astrocytoma is classified as a GBM and
will generally contain a variety of cell types, microvascular proliferation (MVP),
endothelial hyperplasia and hypertrophy, glomeruloid vessels and cellular necrosis17.
MVP is the formation of a new blood supply to the tumor and has been causally linked
to other significant characteristics of GBMs, including hypoxia-induced gene
expression changes and the expression of cytokines such as vascular endothelial
growth factor (VEGF)17. MVP is linked to the appearance of necrosis within the tissue.
All of these morphological conditions can be visualized using histochemical techniques
to more accurately predict overall survival of a patient17. However, histochemical
analysis is limiting because it does not provide information regarding the expression of
particular oncogenes or tumor suppressors within the tumor. Because of the
heterogeneity of cells in GBM tumors, the identification of particular cell types,
oncogenes, and tumor suppressor proteins is critical for effective therapeutic
approaches. Such an approach, if available, would give health care providers critically
important information regarding tumor treatment and possibly improve patient
outcomes. To this end, we propose to utilize immunohistochemical analysis of human
tumors and attempt to correlate the known severity of human GBM tumors with the
7

expression of three cancer cell markers: IDH1-R132H, MGMT, and Basigin.
IDH1
The human genome possesses five IDH genes that give rise to different isozymes
of the IDH protein, including IDH1, IDH2, IDH3A, IDH3B and IDH3G18. In cells, the
IDH1 and IDH2 proteins both function as homodimers by binding with an identical
protein subunit to initiate catalytic activity. The three IDH3 isozymes form dimers
composed of either two alpha subunits, or one beta and one gamma subunit. IDH
proteins function within both the cytosol (IDH1) and mitochondria (IDH2 and IDH3) to
generate reduced nicotinamide adenine dinucleotide phosphate, NADPH, from
NADPH+18. IDH1 to catalyze the oxidative decarboxylation of isocitrate to alphaketoglutarate (α-kg) 11. IDH2 and IDH3 proteins function within the mitochondria in the
Kreb cycle by converting isocitrate to α-KG and reducing Nicotinamide adenine
dinucleotide NAD+ to NADH11. The Kreb cycle is utilized by cells to generate
adenosine triphosphate molecules through different enzymatic reactions.
The most common IDH mutation found in GBMs is an IDH1 point mutation that
converts the arginine residue at position 132 to histidine, called IDH1 R132H 19. This
IDH1 mutation is also found in other cancers including acute myelogenous leukemia
(AML), cholangiocarcinoma, cartilaginous tumors, prostate cancer, papillary breast
carcinoma, acute lympoblastic leukemia (ALL), angioimmunoblastic T-cell lymphoma,
and primary myelofibrosis11. IDH1 R132H mutations are present within 55% to 80% of
grade II and III gliomas and are commonly present within secondary GBMs. GBM
patients that carry the IDH1 R132H mutation experience improved survival following
maximal resection of the tumor 20. Thus, knowledge of the mutation status for IDH1 in
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brain cancers can lead to a better prognosis for patients. The effect of the R132H
mutation is the production of the oncometabolite 2-hydroxyglutarate (2-HG; see also
figure 1) 21.
The production of 2-HG induces changes in DNA methylation pathways and
gene expression in cell, ultimately, promoting tumorigensis. Known as the CpG island
methylator phenotype (CIMP), 2-HG induced DNA methylation is an indirect result of
the IDH R132H mutation. CIMP is correlated with widespread hypermethylation in
genes at specific loci 22. It is currently unclear how the IDH1 mutation initiates tumor
growth and lead to CIMP in any type of cancer 21. Even though mutant IDH1 is viewed
as an oncogene, information about its presence within a tumor can be helpful as patients
treated with Telozolomide (TMZ) and radiation can experience greatly improved
survival times23.
MGMT and Temozolomide
MGMT is an enzyme that removes chemical adducts from DNA, thus preventing
damage to the DNA. This DNA repair enzyme, when present in tumors, can reverse the
DNA damaging effects of chemotherapeutics such as TMZ 12. Thus, increased levels of
the MGMT enzyme correlate with poor responses to TMZ. Most cells express MGMT
enzymes, and the expression of the MGMT gene can be induced by DNA damage 24.
Interestingly, some cells will exhibit greatly reduced levels of the MGMT protein as a
result of MGMT promoter methylation events25. In such cells, the reduction of MGMT
enzyme levels allows for TMZ-induced DNA damage and subsequently apoptotic cell
death. The expression level of MGMT effects the size of tumors. MGMT promoter
methylation and reduced MGMT protein tend to be smaller in size and respond more
positively to treatment. In contrast, when the MGMT promoter is not methylated tumors
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are larger due to the lack of damage to cellular DNA26.
As mentioned previously, the primary chemotherapeutic agent utilized to treat
GBM tumors is TMZ. TMZ induces the alkylation or methylation of DNA at the N7
position of guanine, N3 position of adenine, and the O6 position of guanine. When the
O6 guanine residue becomes methylated it constitutes nearly all of the activity of TMZ
but is only five percent of the total adducts added to the DNA. The methylation of
guanine causes a mismatch pairing with guanine and tyrosine, triggering apoptotic death
of rapidly growing cells such as GBM tumor cells (Figure 2)4. The introduction of TMZ
in 2007 for GBM patients resulted in the greatest improvement in patient survival ever
observed for this deadly cancer 12. Unlike most chemotherapeutics, TMZ is readily
absorbed through oral administration and can easily cross the blood brain barrier. Within
the body, TMZ is converted to the active compound 5-(3-dimethyl-1-triazenyl)
imidazole-4-carboxamide (MITIC), and the conversion of TMZ to MITIC is pH
dependent (Figure 3) 25. MITIC’s main sites of methylation are the N7 position of
guanine, the N3 position of adenine and the O6 position of guanine4. Cell cycle
checkpoint regulators recognize this damage to the DNA and halt the cell cycle.
However, the overexpression of MGMT enzymes can reduce the effectiveness of
TMZ’s effects as the MGMT enzymes repair DNA modifications produced by TMZ 27.
Therefore, information regarding the expression level of MGMT in tumors is central to
predicting the effectiveness of TMZ treatment. DNA sequencing of tumor genomes has
revealed that MGMT promoter cytosine methylation levels can predict responses to
TMZ treatment. Non-methylated MGMT promoter results in elevated expression of the
MGMT gene, and thus a reduced responsiveness to TMZ 24. Therefore, developing
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methodologies to identify tumors that express elevated levels of MGMT is central to
determining the potential effectiveness of TMZ treatment. Progression free survival
(PFS) and overall survival (OS) have been shown to be superior with MGMT promoter
methylation and standard care 23.
Basigin
Basigin is a transmembrane glycoprotein with many different cellular functions.
Known by many different acronyms, including EMMPRIN and CD147, Basigin is
involved in processes such as sexual reproduction, neural function, inflammation, and
tumor invasion28. Tumors with increased Basigin expression correlate positively with an
aggressive invasive phenotype 28. Elevated Basigin expression in tumors stimulates
surrounding tissues to express vascular endothelial growth factor (VEGF), which
promotes neoangiogenesis, or the formation and growth of new blood vessels 29.
Additional evidence demonstrates that elevated Basigin stimulates the expression of
matrix metalloproteinase (MMP) enzymes needed for remodeling of the extracellular
matrix of the tissue surrounding the tumor 30. Basigin protein functions in a paracrine
manner to stimulate surrounding tissues to produce other molecules needed by the tumor
to grow and spread. Thus, stimulating other cells to remodel the extracellular matrix and
surrounding tissue.
It may seem counterintuitive that a transmembrane glycoprotein can function as
a paracrine signaling molecule, but it is well established that Basigin can be released
from the surface of tumor cells via microvesicle shedding (Figure 4). In fact, there has
been an explosion of data demonstrating that most cells release some form of
microvesicle (either membrane microvesicles or exosomes) that can stimulate
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surrounding tissues to alter their activity 31. The release of microvesicles from tumors
containing Basigin protein elevates the expression of metalloproteinase enzymes in
surrounding cells and promotes remodeling of the extracellular matrix to allow for
tumor growth and spread32. This phenomenon suggested that there must be a basigin
receptor on cells, and Belton et. al., showed that the cell surface Basigin protein was
shown to function as a receptor for soluble Basigin protein 33. In response to soluble
Basigin, normal (non-cancerous) cells are stimulated via the p42/44 Map Kinase
signaling pathway resulting in elevated expression and secretion of a number of MMP
gene products. Therefore, aggressive cancers that express and release greater amounts of
Basigin protein are able drive surrounding tissues to synthesize molecules that promote
tumor survival. Finally, increased Basigin expression within tumor cells promotes the
ability of cancer cells to survive chemotherapy directly. This appears to be a direct result
of Basigin’s interaction with P-glycoprotein and ATP-binding casset transporters, or
ABCG transporters that function to remove toxic compounds from cells and thus assist
cell survival pathways in the presence of chemotherapeutic agents34.
Normal human brain tissue expresses little to no Basigin protein, while brain
tumors express elevated levels of Basigin34. Furthermore, patients with GBM tumors
tend to struggle more with daily activities and general cognitive function when their
cancer has higher Basigin levels. This evidence also correlates with reduced overall
survival of patients and suggests that Basigin is a critical marker for tumor severity
and patient outcomes 34. Based upon this evidence, we hypothesized that the severity
of a particular GBM tumor correlates positively with the expression levels of Basigin
and the DNA repair enzyme MGMT, and inversely with the expression of the IDH1
R132H mutant metabolic enzyme. To test this hypothesis, human brain tissues from
12

GBM patients were analyzed for protein expression using immunohistological staining
techniques. The data was collected by confocal microscopy, and quantitatively
analyzed using Imaris imaging software.
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CHAPTER TWO: EXPERIMENTAL DESIGN

Introduction
While Basigin, MGMT, and IDH1 are all expressed in GBMs, it is not yet
known how the levels of expression for each protein affect tumor aggressiveness and
resistance to treatment. For this project, commercially available antibodies specific for
the target proteins were utilized to identify relative expression levels for each in human
tumor samples. GBM cell lines were used to demonstrate that the antibodies specifically
recognize their target proteins using a standard immunoblotting approach. Paraffin
embedded tumor samples were prepared for fluorescent immunohistochemistry and
confocal microscopy to analyze the level of expression. It was expected that increased
expression of Basigin and MGMT would correlate with more aggressive GBM tumors.
While the IDH1 R132H mutation is not always present within primary GBMs (it is often
seen within secondary GBMs), the presence of this mutation would benefit patient
survival if the tumor were fully resected and treated with TMZ and radiation.
Human GBM samples
Glioblastoma samples were provided by the UP Health System- Marquette
(UPHSM). The use of these tissues was approved by UPHSM Institutional Review
Board (IRB) and the Northern Michigan University IRB. The preserved tissue was
collected between 2003 and 2004, and patient information associated with the tumor
samples was expunged from the records prior to use. The initial histological analysis of
the tissues was performed in the Department of Pathology of UPHSM by Dr. John
14

Weiss. Dr. Weiss provided marking of malignant spots of Hematoxylin & Eosin (H&E)
stained tissue sections.
Human GBM Cell Lines
U87MG IDH1 R132H mutant cell line was a kind gift from Horacio Soto at
Geffen Cancer Center at UCLA. The U87MG, LN229, T98 (American Tissue Culture
Collection Manassas, VA), and fibroblast cell line, MSU 1.1 from Michigan State
University. Cell lines were grown in standard conditions of 37°C and 5% CO2 in
complete media, Eagle’s minimal essential medium and Dulbecco’s Modified Eagle’s
Medium (Lonza, Walkersville, MD) with 10% bovine serum (FBS) (Atlanta Biological,
Atlanta, GA) and 1% Penicillin/Streptomycin/Amphotericin B (Gibco, CA) to 80%
confluency in T-75 flasks. Cells were harvested using the trypsin-EDTA method
(Versene, Lonza) and cells pelleted at 300x g. Cell pellets were washed and resuspended
in growth media for replating in tissue cultureware at a ratio of 1/3.
Immunoblotting and Antibodies
Nearly confluent cell monolayers were washed with cold PBS and the cells lysed
using a 1% NP-40 non-denaturing detergent buffer. Lysates were clarified by
centrifugation (20,000xG, 10 minutes, 4°C) and the supernatant collected. Total protein
concentration was determined using the bicinchoninic acid assay (BCA). 10mg of
protein were loaded into the wells of a precast 4-15% SDS-polyacrylamide gels
(BioRad) and resolved at 200volts for approximately 1 hour. The cellular proteins were
transferred from the polyacrylamide gels by electroblotting onto PVDF membranes for
10 hours at 100mA. PVDF membranes were treated with a solution of 5% non-fat dry
milk (NFDM) dissolved in Tris-Buffered Saline containing 0.1% Tween20 (TBST).
15

Blocked membranes were incubated with the primary antibodies (Basigin 1:500,
IDH1m-Dianova 3.33:1000, IDH1 wt 1:500, MGMT 1:500,) overnight at 4°C with
shaking. Visualization of specific proteins was accomplished by staining with a goat
anti-mouse horseradish peroxidase-labeled antibody (Thermo Scientific) for one hour
followed by detection with enhanced chemiluminescence (Pierce Pico
Chemiluminescence Reagent). Films were exposed to the blots for thirty seconds and
five minutes (Five minute exposure images are figures 6-10). Images were obtained
using a Kodak M35A X-OMAT Processor.
The primary antibodies used in this study were as follows: mouse anti-IDH1
(Origene Technologies, Rockville, MD), mouse anti- IDH1-R132H (Millipore,
Darmstadt, Germany), mouse anti-MGMT (Thermo Fisher Scientific, United States),
mouse anti- Basigin (Genetex), and mouse anti-human IDH1 R132H (Dianova,
Germany). The following secondary antibodies were used: donkey anti-mouse
Alexaflour 488 (Jackson ImmunoResearch, West Grove, PA) and donkey anti-mouse
HRP (Thermo Fisher Scientific, United States).
Histochemistry
Paraffin embedded tumor samples were sectioned at 5μm and transferred to glass
slide. Sections were deparaffinazed and rehydrated through graded series of xyleneethanol. The slides were stained with hematoxylin (Richard-Allen Scientific) and eosin
(Richard- Allen Scientific) and then dehydrated through another ethanol-xylene graded
series. Following the final xylene wash, the slides were mounted with Cytoseal 60
(Richard-Allan Scientific) and a glass cover slip. Tissue slides were marked, regraded,
and imaged by Dr. Weiss at UP Health System- Marquette. All tissue blocks that were
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used in this study were confirmed to be GBM tumors.
Immunostaining and confocal imaging
Tissue sections were deparaffinized and rehydrated through graded series of
xylene-ethanol and then washed in PBS three times for ten minutes each. Tissue sections
were blocked with blocking buffer containing donkey serum (Jackson ImmunoResearch)
for one hour. Afterwards, the tissues were incubated with the primary antibodies for
Basigin, MGMT, IDH1 R132H, or IDH1 over-night at 4°C (Basigin 1:500, IDH1mDianova 1:20, IDH1m- Millipore 1:500, IDH1 wt 1:50, MGMT 1:15). Sections were
then incubated with donkey anti-mouse Alexaflour 488 secondary antibody (1:100)
(Jackson ImmunoResearch) for one hour in the dark. A second PBS wash was done,
three times for ten minutes each, and then ProLong Diamond Antifade Mountant with
DAPI (Thermo Scientific) was used to cover slip the sections. Fluorescence intensity of
marked malignant spots were visualized with a confocal microscope (Olympus ix81
FV100).
For analysis of the confocal z-stack scans, the software Imaris (Bitplane,
Zurich, Switzerland) was used. The software was used to highlight the surface area and
intensity of the fluorescence of the nuclei and proteins being tagged. The intensity for
each protein was adjusted and expression was determined through the binding of a
protein to the nuclei (DAPI stain).
Statistical Analysis
The effects of different protein expression in tumor samples from 5 patients
were modeled using “linear mixed models” in R version 3.2.3 (R Core Team 2015)35.
The package “lme4” was used for the analysis36. Two response variables were analyzed
17

in separate models: “area” (area of the expressed protein, in μm2; and “intensity”.
Intensity is based on the fluorescent signal that is being emitted by the Alexafluor 488
antibody. The fixed effect of primary interest was “protein” (4 levels), but “patient” was
also included as random factor to account for variation in protein expression among
subjects. The model was of the type where Y= protein + (1 | patient), which models a
varying-intercept group effect using the variable “patient”. Least squares means (lsm
package in R) and Tukey’s Method were used to estimate means and differences
between means adjusted for variation among patients. Linear mixed models were used
because the design was unbalanced (some proteins were not present in all patients), and
the cells measured were not independent. Linear mixed models are able to model the
error structure to avoid violating assumptions inherent in typical ANOVAs.
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CHAPTER THREE: RESULTS

Hematoxylin and Eosin Analysis
H&E staining was conducted on the five different GBM tumors that were used
in this study. These slides were initially examined and by Dr. Weiss at UPHSM and the
boundaries between malignant and nonmalignant tissues were marked. The malignant
portions of the tumor were then imaged on the Olympus laser confocal microscope at
NMU. Images of these H&E stained slides are shown in Figure 5. Different forms of
vascularity and cell formation can be seen throughout the malignant portions of the
tissue (Figure 5A-E).
Protein expression within GBM cell lines
Immunoblotting of GBM cell lines with the antibodies used in this study are
shown in Figures 6-10. Equivalent amounts of soluble protein for the five cell lines used
were loaded in each lane of the immunoblots. The results demonstrate the presence of
bands at the anticipated molecular weights for each of the proteins. The DNA repair
enzyme MGMT was expressed by the T98 and MSU 1.1 cell lines, but was not detected
in any other cell line (Figure 6). The cell surface glycoprotein Basigin was expressed
within all lines and clearly demonstrated the presence of two glycosylated forms: a high
glycosylated form at ~45-60kDa and a low glycosylated form at ~35 kDa (Figure 7).
The IDH1 wild type enzyme was expressed within all cell lines used. The antibody
specific for the wildtype IDH1 cannot distinguish between the R132H IDH mutant and
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the wild type enzyme. Therefore, the protein sample from the U87MG R132H cell line
shows a significant increase in the IDH1 protein as this cell line overexpresses the
R132H protein (Figure 8). The IDH1 R132H mutation was expressed within the U87
mutant cell line and was not present in any other (Figure 9). Figure 10 is an immunoblot
showing the relative expression for the housekeeping gene GAPDH to show the relative
amounts of protein within the cell lysates.
Protein Expression within GBM tissue samples
Figures 11-15 represent images from the immunohistochemistry experiments
performed on tissue sections from five different human GBM tumor samples. These
different tissue samples are shown in Figure 11 = Block 5625, Figure 12 = Block 3331,
Figure 13 = Block 4946, Figure 14 = Block 10168, and Figure 15 = Block 8072). In
each series of figures, the tissues were probed with the following antibodies: A =
Basigin, B = IDH1 wild type, C = IDH1 R132H (Millipore), D = IDH1 R132H
(Dianova), E = MGMT.
All GBM tissues expressed the proteins Basigin, IDH1, IDH1 R132H, and
MGMT (Fig11-15). The level of fluorescence within each slide varies in the photos, but
can clearly be seen. It should be noted that the IDH1 mutations were imaged using two
antibodies from different manufacturers (Dianova and Millipore) and the images using
both antibodies are shown. Some of the tissue blocks were initially thought to lack
expression of the IDH1 mutation using the Millipore antibody, but when reimaged using
the primary antibody from Dianova, staining was observed.
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Analysis of Protein Expression in GBM Samples
Figure 16 represents the quantitative data from the fluorescent images shown in
figures 11-15. The fluorescent emission from each slide was quantified using the Imaris
software package. For this work, the fluorescence from individual cells was measured on
Imaris, and the mean values for each protein provided by Imaris were adjusted for the
variation among patients. When the data set for protein area was being analyzed, there
were variations among the data points. The log of each point was taken and averaged for
the final data set. The Tukey Method, a statistical single-step comparison method, was
used to compare the means of the proteins in question. These means were also adjusted
for the variation among patients. There were significant differences in intensity mean
between Basigin and IDH1 m (t ratio= 3.271, df= 493.80, P=0.006), IDH1 m and IDH1
wt (t ratio= -2.679, df= 492.09, P=0.038), and IDH1 m and MGMT (t ratio=-2.830, df=
492.15, P=0.025). No other pairs were significantly different. When the average for
log10 of the area means were taken there were significant difference between Basigin
and IDH1 wt (P=0.006) and IDH1 wt and MGMT (P=0.0188).
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CHAPTER FOUR: DISCUSSION

IDH1 And IDH1 R132H mutant expression in GBM
The use of the human cell lines for immunoblot analysis provided a method for
demonstrating the specificity of the antibodies used later in the analysis of the human
GBM tissues. For the anti-IDH1 antibodies, what was learned from this analysis was
that the anti-IDH1 antibody that is designed to recognize the R132H point mutation
was highly specific and did not detect the wild-type IDH1 protein in any of the cell
lines used (Figure 9). This antibody detected 10ng of a recombinant IDH1 R132H
peptide and the IDH1 R132H isoform overexpressed in the cell line. This cell line was
a gift from Horacio Soto at Geffen Cancer Center at UCLA39. These cells overexpress
this mutant IDH1 R132H isoform (which I will refer to as ‘IDH1m’) in a background
of wild-type IDH1 produced by the cell. Both the wildtype and the mutant isoform
possess identical molecular weights and could not be distinguished from each other
without the use of monoclonal antibodies. Immunoblotting with the wild-type antiIDH1 antibody detected the IDH1 protein in all the cell lines, including the IDH1m
isomer in the mutant cell line. This is consistent with the fact that this antibody
recognizes an epitope that is shared in all forms of the IDH1 protein (mutant and wildtype). Thus, in lane 2 of figure 8, the antibody produced a strong signal as it recognized
epitopes on the over-expressed recombinant protein. Within human tissues, the
presence of the R132H mutation leads to the production of the oncometabolite 2hydroxyglutarate (2-HG) and often results in the loss of the wild-type IDH1 allele 10.
The presence of fluorescent signals on the same GBM tissues using both wildtype and
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mutant IDH1 antibodies suggests that both isoforms are present within the tissues
(Figures 11-16, panels B, C & D). However, it is also possible that some of the protein
recognized by the wild-type antibody actually represents the IDH1m isoform.
Unfortunately, clarification of this issue was outside of the technical ability in this
study. Nonetheless, the immunoreactivity with the IDH1m antibody is highly specific,
and the results from Figure 11-16 panel D clearly show the presence of this mutant
isoform. The significance of this result is that this isoform is usually found in lowgrade brain tumors and secondary GBMs, and patients with this mutation experience a
longer survival rate with full resection of the tumor and aggressive chemotherapy.
Basigin expression in GBMs
The cell surface glycoprotein named Basigin has recently been an area of
interest as a cancer antigen34. Known also as extracellular matrix metalloproteinase
inducer (EMMPRIN) or CD147, the expression of basigin protein in GBM tumors is
generally very high34. Elevated Basigin levels correlate with increased angiogenesis,
cell proliferation and cell invasion leading to more aggressive tumors with a more fatal
diagnosis37. Immunostaining of the GBM tissues demonstrated a significant difference
in the expression levels of Basigin and IDH1m, with IDH1m expression reduced in
cells with elevated Basigin. This data supports our hypothesis that these two proteins
are inversely correlated and may have separate and opposing effects in tumor growth.
Further research is needed to show the exact correlation between the two proteins. If
there is a decreased amount of Basigin being expressed when IDH1m is present, either
in a heterozygous or homozygous fashion, this would help explain the reason why
GBMs with this mutation respond to treatment. The decreased amount of Basigin
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would not promote as much angiogenesis and cell proliferation, therefore forming a
less aggressive and slower growing tumor.
MGMT Expression
Immunoblot analysis of the DNA repair enzyme MGMT within the human cell
lines demonstrated that this protein is expressed in the GBM cell line T98 and the
human fibroblast cell line MSU 1.1. A lack of MGMT expression in particular cells is
commonly a result of MGMT promoter methylation status, as the promoter methylation
silences MGMT gene expression 40. The cell lines LN229 and U87MG did not express
MGMT protein suggesting that the MGMT promoters in these cell lines are
methylated. To confirm this result, additional experiments would be necessary,
including bisulfite DNA sequencing to demonstrate the methylation of cytosine
residues within the MGMT promoter. Cells that maintain expression of the MGMT
gene can repair DNA damaged by alkylating agents such as TMZ. Therefore, blocking
MGMT production or function would enhance the effectiveness of chemotherapeutics
like TMZ. Based upon the statistical analysis of the MGMT expression in GBM tissues
(Tukey’s test), MGMT levels are significantly reduced in cells expressing of IDH1m.
Once again, this pattern of protein expression supports the stated hypothesis that
MGMT levels are inversely correlated with IDH1m expression levels. At this time, we
cannot yet explain how the presence of IDH1 R132H enzyme affects expression levels
of Basigin or MGMT, nor how it may alter tumor growth and repair.
Protein Expression within Human GBM tumors
There was variation within the protein expression in the GBM tissues samples.
When observing the differences in mean intensity of each protein, there was a
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significant difference between IDH1m and all other proteins. Basigin, IDH1wt, and
MGMT were not significantly different from one another. Among the five patients,
there was overall stronger fluorescent signal for Basigin, IDH1wt and MGMT. When
examining the area of each protein in the tissues, there were significant differences
between IDH1 wt and MGMT, and IDH1 wt and Basigin. Since this study was mainly
comparing the difference of expression in IDH1 mutation and Basigin expression, it
was surprising to find differences between IDH1 wt and other proteins. The difference
between the mean intensity and area could be explained by the difference in
measurement. Mean intensity is measuring the brightness of the secondary antibody
and the area is measuring the size of the protein bound by the antibodies. This may not
give the most accurate depiction of what is truly happening within the tumors.
In future studies it would be best to utilize different primary antibodies that
originate from different host animals. This would allow us to probe each tissue
block with multiple antibodies simultaneously to allow for the measurement of
protein expression in each cell of a tumor. This approach would allow for a more
powerful statistical analysis of the correlation between protein expression, tumor
growth and patient survival.
CONCLUSION
In conclusion, this study has shown that there is a difference among IDH1
mutation expression and Basigin, IDH1 wt and MGMT. Further investigation on these
findings is needed and a larger patient group should be used. Patient history may also
be useful in future studies to assist in background knowledge of the patients. Having
the background knowledge of patients may allow for more of a selective process when
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choosing tumor blocks and allow for a control group (GBM with IDH1m and without).
Finding more correlations between these proteins may lead to better treatments and
more advantageous diagnoses leading to a longer overall survival, and possibly, better
quality of life for GBM patients. This could be accomplished by increasing the amount
of tumor suppressor gene mutations and oncogene overexpression that are tested for
after tumor resection. Also, adding to the forms of treatment and possible
chemotherapies that target other aspects of GBM tumors.
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Figure 1. Isocitrate dehydrogenase (IDH) enzyme function in human cells. This
figure illustrates the role of the IDH enzymes in cellular metabolism in both the
mitochondria and the cytoplasm of the cell. The enzyme IDH1 primarily functions in
the cytoplasm of the cell where it is involved in the production of NADPH and
-ketoglutarate. Image adapted from Dimitrov et al. Int J Med Sci 2015; 12(3):201213. doi:10.7150/ijms.11047

27

Figure 2. Common temozolomide-induced DNA lesions appear on guanine
and adenine. N7-methylguanine, N3-methyladenine and O6-methylguanine
DNA adducts account for roughly 70%, 10% and 5% of these lesions
respectively. The enzyme MGMT mediates removal of the O6-methylguanine
adducts. Adapted from Lawrence et al 2015 4.

28

Figure 3. Temozolomide is converted to MTIC within the body and contributes
methyl or alkyl chemical groups on DNA. Adapted from Agarwala et al. The
Oncologist April 2000 vol. 5 no. 2 144-151.
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Figure 4. Microvesicles and exosomes are membrane vesicles released from
cells to the extracellular space. Image adapted from Raposo & Stoorvogel J. Cell
Biol. Vol. 200 No. 4 373–383 www.jcb.org/cgi/doi/10.1083/jcb.201211138
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Figure 5A. H&E Staining from Block 5652. This image illustrates
increased blood vessel growth (arrows) and formation and increased
cell density within the sample. High vascularity is a common sign of
GBM tumors and many tumors will develop their own blood supply
when they become large enough.
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Figure 5B. H&E Staining from Block 3331. This image shows
high cell density on the left side of the image and necrosis (arrows)
on the right where the arrows are located. Necrosis is a very common
characteristic of GBM tumors.
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Figure 5C. H&E Staining from Block 4946. This image of a
GBM tumor shows gemistocytic astrocytes (arrows) that are
characterized by their swollen cytoplasmic mass. These types of
astrocytes are present when there is scarring within the CNS tissue
and can lead to confusion, drowsiness, stupor or coma.
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Figure 5D. H&E Staining from Block 10168. This tissue is displaying
glomeruloid vascularity, indicated by the arrows. This form of vasculature
is conducive with angiogenesis and can signify the presence of elevated
levels of vascular endothelial growth factor (VEGF) within a tumor.
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Figure 5E. H&E Staining from Block 8072. This GBM tissue is
displaying high cell density and this is believed to be the outer area
of the tumor.
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Figure 11A. Immunofluorescence of basigin in block 5625. The control
image is showing the absence of the secondary fluorescent antibody
binding. The merged image is showing both DAPI staining and basigin
expression, along with the outlines of the cell bodies.
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Figure 11B. Immunofluorescence of IDH1 wild type in block 5625.
The control image is showing the absence of the secondary fluorescent
antibody binding. The merged image is showing both DAPI staining and
IDH1 wild type expression, along with the outlines of the cell bodies.
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Figure 11C. Immunofluorescence of IDH1 mutation in block 5625.
The control image is showing the absence of the secondary fluorescent
antibody binding. The merged image is showing both DAPI staining and
IDH1 mutation expression, along with the outlines of the cell bodies.

43

Figure 11D. Immunofluorescence of IDH1 mutation in block 5625.
The control image is showing the absence of the Dianova fluorescent
antibody binding. The merged image is showing both DAPI staining and
IDH1 mutation expression, along with the outlines of the cell bodies.
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Figure 11E. Immunofluorescence of MGMT in block 5625. The control
image is showing the absence of the secondary fluorescent antibody
binding. The merged image is showing both DAPI staining and MGMT
expression, along with the outlines of the cell bodies.
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Figure 12A. Immunofluorescence of Basigin in block 3331. The control
image is showing the absence of the secondary fluorescent antibody
binding. The merged image is showing both DAPI staining and Basigin
expression, along with the outlines of the cell bodies.
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Figure 12B. Immunofluorescence of IDH1 wild type in block 3331.
The control image is showing the absence of the secondary fluorescent
antibody binding. The merged image is showing both DAPI staining and
IDH1 wild type expression, along with the outlines of the cell bodies.
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Figure 12C. Immunofluorescence of IDH1 mutation in block 3331.
The control image is showing the absence of the secondary fluorescent
antibody binding. The merged image is showing both DAPI staining and
IDH1 mutation expression, along with the outlines of the cell bodies.
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Figure 12D. Immunofluorescence of IDH1 mutation in block 3331.
The control image is showing the absence of the Dianova fluorescent
antibody binding. The merged image is showing both DAPI staining and
IDH1 mutation expression, along with the outlines of the cell bodies.
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Figure 12E. Immunofluorescence of MGMT in block 3331. The control
image is showing the absence of the secondary fluorescent antibody
binding. The merged image is showing both DAPI staining and MGMT
expression, along with the outlines of the cell bodies.
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Figure 13A. Immunofluorescence of basigin in block 4946. The control
image is showing the absence of the secondary fluorescent antibody
binding. The merged image is showing both DAPI staining and basigin
expression, along with the outlines of the cell bodies.
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Figure 13B. Immunofluorescence of IDH1 wild type in block 4946.
The control image is showing the absence of the secondary fluorescent
antibody binding. The merged image is showing both DAPI staining and
IDH1 wild type expression, along with the outlines of the cell bodies.
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Figure 13C. Immunofluorescence of IDH1 mutation in block 4946.
The control image is showing the absence of the secondary fluorescent
antibody binding. The merged image is showing both DAPI staining and
IDH1 mutation expression, along with the outlines of the cell bodies.
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Figure 13D. Immunofluorescence of IDH1 mutation in block 4946.
The control image is showing the absence of the Dianova fluorescent
antibody binding. The merged image is showing both DAPI staining and
IDH1 mutation expression, along with the outlines of the cell bodies.
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Figure 13E. Immunofluorescence of MGMT in block 4946. The control
image is showing the absence of the secondary fluorescent antibody
binding. The merged image is showing both DAPI staining and MGMT
expression, along with the outlines of the cell bodies.
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Figure 14A. Immunofluorescence of Basigin in block 10168. The
control image is showing the absence of the secondary fluorescent
antibody binding. The merged image is showing both DAPI staining and
Basigin expression, along with the outlines of the cell bodies.
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Figure 14B. Immunofluorescence of IDH1 wild type in block 10168.
The control image is showing the absence of the secondary fluorescent
antibody binding. The merged image is showing both DAPI staining and
IDH1 wild type expression, along with the outlines of the cell bodies.
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Figure 14C. Immunofluorescence of IDH1 mutation in block 10168.
The control image is showing the absence of the secondary fluorescent
antibody binding. The merged image is showing both DAPI staining and
IDH1 mutation expression, along with the outlines of the cell bodies.
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Figure 14D. Immunofluorescence of IDH1 mutation in block 10168.
The control image is showing the absence of the Dianova fluorescent
antibody binding. The merged image is showing both DAPI staining and
IDH1 mutation expression, along with the outlines of the cell bodies.
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Figure 14E. Immunofluorescence of MGMT in block 10168. The
control image is showing the absence of the secondary fluorescent
antibody binding. The merged image is showing both DAPI staining and
MGMT expression, along with the outlines of the cell bodies.
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Figure 15A. Immunofluorescence of Basigin in block 8072. The control
image is showing the absence of the secondary fluorescent antibody
binding. The merged image is showing both DAPI staining and Basigin
expression, along with the outlines of the cell bodies.
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Figure 15B. Immunofluorescence of IDH1 wild type in block 8072.
The control image is showing the absence of the secondary fluorescent
antibody binding. The merged image is showing both DAPI staining and
IDH1 wild type expression, along with the outlines of the cell bodies.
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Figure 15C. Immunofluorescence of IDH1 mutation in block 8072.
The control image is showing the absence of the secondary fluorescent
antibody binding. The merged image is showing both DAPI staining and
IDH1 mutation expression, along with the outlines of the cell bodies.
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Figure 15D. Immunofluorescence of IDH1 mutation in block 8072.
The control image is showing the absence of the Dianova fluorescent
antibody binding. The merged image is showing both DAPI staining and
IDH1 mutation expression, along with the outlines of the cell bodies.
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Figure 15E. Immunofluorescence of MGMT in block 8072. The control
image is showing the absence of the secondary fluorescent antibody
binding. The merged image is showing both DAPI staining and MGMT
expression, along with the outlines of the cell bodies.
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Figure 16A. Significant differences were found between the mean intensity of Basigin
and IDH1 m (t ratio= 3.271, df= 493.80, P=0.006), IDH1m and IDHwt (t ratio=3.271,
df=492.09, P=0.038), and IDH1m and MGMT (t ratio=2.830, df=492.15, P=0.025).
No other pairs were found to be significantly different.

Figure 16B. Using the log 10 of area, significant differences were found between
Basigin and IDH1 wt (P=0.006) and IDH1wt and MGMT (P=0.0188). Means with the
same letter are not significantly different.
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